

EPIDEMIOLOGICAL PREDICTORS OF THERAPEUTIC RESPONSE IN HEAD AND **NECK CANCER**





FLÁVIA NASCIMENTO DE CARVALHO¹; IZABELLA COSTA²; FERNANDO DIAS²; ANKE BERGMANN¹; LUIS FELIPE RIBEIRO PINTO¹ ¹Molecular Carcinogenesis Program – National Cancer Institute, Rio de Janeiro, Brazil; ²Head and Neck Surgery – National Cancer Institute, Rio de Janeiro, Brazil

INTRODUCTION

In developing countries, tumors of the head and neck are diagnosed in advanced stages, compromising survival and therapeutic response.

Treatment Modalities		Stage					
	Ι	II	III	IV	IUtal		
surgery	46 (64.8)	32 (43.2)	11 (12.9)	27 (11.0)	116 (24.4)		

METHODS AND RESULTS

To evaluate the factors related to the therapeutic response in head and neck cancer we carried out a prospective cohort study, with 488 cases diagnosed with head and neck cancer at the National Cancer Institute (INCA) between March 2012 and July 2014, who accepted to participate in the multicenter project, called interCHANGE, coordinated by the International Agency for Research on Cancer (IARC). Sociodemographic, clinical, pathological and lifestyle related variables were collected. The therapeutic response (the presence or absence of disease at the first consultation after the first line treatment) was considered as a dependent variable. A descriptive analysis of the data was performed. Univariate logistic regression analysis was performed in order to obtain the predictive factors of the therapeutic response. The variables with p<0.20 were selected for the multiple model and p<0.05 was considered for the final model. Statistical package SPSS 20.0 was used for the analyzes. The project was approved by INCA's research ethics committee under registration 065/2012. The majority of the individuals were 60 years or older (52.7%), male (80.1%), white (62.7%), low educational status (63.4%) and body mass index (BMI) < 25 kg/m² (65,2%). About 87% of the cases reported being smokers or former and almost 79% were consumers or former users of alcohol. Almost all cases presented squamous cell carcinoma (SCC) and for all topographies the advanced staging was predominant (69.5%). For initial stages, the exclusive surgery was more often employed. The other therapeutic modalities were indicated for advanced stages. Oropharynx and hypopharynx cancers presented about 40% evidence of disease after the end of the first line treatment. After adjustment for age and staging, BMI and alcohol consumption were predictive factors of therapeutic response for all topographies. Cases with a BMI < 25 kg / m² had a 2.10 fold (1,289 -3,428) higher probability of a worse therapeutic response and alcohol users presented a 1.91 fold (1.030) - 3.536) higher risk for this outcome.

surgery + RT	8 (11.3)	24 (32.4)	30 (35.3)	85 (34.7)	147 (30.9)
surgery + RT+ QT	2 (2.8)	6 (8.1)	2 (2.4)	11 (4.5)	21 (4.4)
RT	8 (11.3)	5 (6.8)	11 (12.9)	41 (16.7)	65 (13.7)
$\mathbf{RT} + \mathbf{QT}$	3 (4.2)	1 (1.4)	19 (22.4)	44 (18.0)	67 (14.1)
QT		1 (1.4)	1 (1.2)	2 (0.8)	4 (0.8)
surgery + QT	1 (1.4)		_	1 (0.4)	2 (0.4)
out of INCA	3 (4.2)	1 (1.4)	3 (3.5)	11 (4.5)	18 (3.8)
without treatment		4 (5.4)	8 (9.4)	23 (9.4)	35 (7.4)

*The differences means missing values.

Table 2. Treatment modalities by stages.



Table 1. Absolute and relative frequencies of demographic and clinical variables.

	Topographies (CID-10)						
N	Lip	Oral Cavity	Oropharynx	Hypopharynx	Larynx	Total	
variaveis	(C00)	(C01 – C06)	(C09 - C10)	(C12 – C13)	(C32)	n (%)*	
	n (%)*	n (%)*	n (%)*	n (%)*	n (%)*		
Age							
<60	2 (28.6)	109 (46.8)	39 (60.0)	11 (55.0)	70 (42.9)	231 (47.3)	
>ou= 60	5 (71.4)	124 (53.2)	26 (40.0)	9 (45.0)	93 (57.1)	257 (52.7)	
Sex							
male	6 (85.7)	170 (73.0)	59 (90.8)	17 (85.0)	139 (85.3)	391 (80.1)	
female	1 (14.3)	63 (27.0)	6 (9.2)	3 (15.0)	24 (14.7)	97 (19.9)	
Race							
white	6 (85.7)	147 (63.1)	44 (67.7)	11 (55.0)	98 (60.1)	306 (62.7)	
Others	1 (14.3)	86 (36.9)	21 (32.3)	9 (45.0)	65 (39.9)	182 (37.3)	
School							
< 8 yrs	4 (57.1)	139 (59.7)	42 (64.6)	12 (60.0)	112 (69.1)	309 (63.4)	
> ou = 8 yrs	3 (42.9)	94 (40.3)	23 (35.4)	8 (40.0)	50 (30.9)	178 (36.6)	
BMI							
low weight,	4 (57 1)	148 (63 5)	44 (69 8)	13 (65 0)	107 (66 0)	316 (65 2)	
eutrophic			(0).0)			510 (05.2)	
overweight, obese	3 (42.9)	85 (36.5)	19 (30.2)	7 (35.0)	55 (34.0)	169 (34.8)	
Smoke	- /		/				
smoker, former	6 (85.7)	194 (83.3)	57 (87.7)	17 (85.0)	152 (93.3)	426 (87.3)	
never	1 (14.3)	39 (16.7)	8 (12.3)	3 (15.0)	11 (6.7)	62 (12.7)	
Alcohol							
consumer, former	6 (85.7)	176 (75.5)	57 (87.7)	19 (95.0)	127 (77.9)	385 (78.9)	
never	1 (14.3)	57 (24.5)	8 (12.3)	1 (5.0)	36 (22.1)	103 (21.1)	
Morphology							
SCC	6 (85.7)	226 (97.0)	65 (100.0)	20 (100.0)	162 (99.4)	479 (98.2)	
others	1 (14.3)	7 (3.0)	_	_	1 (0.6)	9 (1.8)	
Stage							
Ι	2 (28.6)	36 (16.2)	3 (4.7)	2 (10.5)	28 (17.3)	71 (14.9)	
II	5 (71.4)	41 (18.5)	4 (6.2)	2 (10.0)	22 (13.6)	74 (15.6)	
III	_	37 (16.7)	11 (17.2)	4 (20.0)	33 (20.4)	85 (17.9)	
IV		108 (48.6)	46 (71.9)	12 (60.0)	79 (48.8)	245 (51.6)	

*The differences means missing values.

Figure 2. Cancer evidence and remission by topographies.

Table 3. Risk factors for inadequate treatment response.

Variáveis	OR*	IC 95%		p valor	
BMI (<25kg/m² x ≥25kg/m²)	2,10	1,289	3,428	0,003	
Alcohol consumption (active+former x never)	1,91	1,030	3,536	0,040	

* adjustment for age and staging

CONCLUSION

Low BMI than 25 kg / m^2 and alcohol consuption predicted a worse therapeutic response.





Figure 1. Distribution of staging by topographies

1. Ferlay J, Soerjomatarm I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: E359–E386. 2. INSTITUTO NACIONAL DE CÂNCER. INCA. Estimativa 2016: incidência de câncer no Brasil. Rio de Janeiro; 2015.

3. Yan W, Wistuba II, Emmert-Buck MR, Erickson H. Squamous cell carcinoma – simitarities and differences among anatomical sites. Am J Cancer Res. 2011; 3: 275-300.

4. Choi SH, Terrell JE, Fowler KE, McLean AS, Ghanem T, Wolf GT, Bradford CR, Taylor J, Duffy SA. Socioeconomic and other demographic disparities predicting survival among head and neck cancer patients. PLoS ONE 11(3): e0149886. doi:10.1371/journal.

Sources of finantial suport: FAPERJ, Swiss Bridge, Ministério da Saúde

Projeto Gráfico: Setor de Edição e Informação Técnico-Científica / INCA



